ARTICLE | Clinical News
Elagolix: Phase II data
May 25, 2009 7:00 AM UTC
Follow-up data from the Phase II PETAL trial showed that elagolix sustained safety and efficacy after treatment was stopped. Patients received 150 mg once-daily elagolix, 75 mg twice-daily elagolix or...